TY - JOUR
KW - *Cardiovascular Diseases/epidemiology/prevention & control
KW - *Diabetes Mellitus, Type 2/complications/drug therapy
KW - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
KW - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
KW - Glucose
KW - *Heart Failure/epidemiology
KW - Hospitalization
KW - Humans
KW - *Myocardial Infarction
KW - Primary health care
KW - *Renal Insufficiency, Chronic/complications/epidemiology
KW - Retrospective Studies
KW - Sodium
KW - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
KW - *Symporters
KW - United Kingdom/epidemiology
KW - Cardiovascular disease
KW - clinical trial
KW - dapagliflozin
KW - diabetes complications
KW - dipeptidyl peptidase-4 inhibitor
KW - heart failure
AU - I. Idris
AU - R. Zhang
AU - J. Mamza
AU - M. Ford
AU - T. Morris
AU - A. Banerjee
AU - K. Khunti
AD - Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.
Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Institute of Health Informatics, University College, London, UK.
Department of Cardiology, University College London Hospitals, London, UK.
Diabetes Research Centre, University of Leicester, Leicester, UK.
AN - 33973690
BT - Diabetes Obes Metab
C2 - PMC8518855
DO - 10.1111/dom.14437
DP - NLM
ET - 2021/05/12
LA - eng
M1 - 10
N1 - 1463-1326
Idris, Iskandar
Zhang, Ruiqi
Mamza, Jil Billy
Ford, Mike
Morris, Tamsin
Banerjee, Amitava
Khunti, Kamlesh
Orcid: 0000-0003-2343-7099
DH_/Department of Health/United Kingdom
Journal Article
Research Support, Non-U.S. Gov't
Diabetes Obes Metab. 2021 Oct;23(10):2207-2214. doi: 10.1111/dom.14437. Epub 2021 Aug 2.
PY - 2021
SN - 1462-8902 (Print)1462-8902
SP - 2207
EP - 2214
T2 - Diabetes Obes Metab
TI - Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease
VL - 23
ER -